LRRK2 and Parkinson disease: In contrast, there are several clinical trials underway for evaluating whether LRRK2 inhibitors or antisense oligonucleotide therapies confer disease-modifying benefits for PD patients (77, 78) and our analysis would suggest that patients harboring PINK1 mutations would not benefit from LRRK2 inhibitors and highlight the need for patient stratification for molecular targeted clinical trials in PD.